Search

Your search keyword '"DiSilvestro, Paul A."' showing total 34 results
Start Over Author "DiSilvestro, Paul A." Journal journal of clinical oncology
34 results on '"DiSilvestro, Paul A."'

1. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Author

Powell, Matthew A, Filiaci, Virginia L, Hensley, Martee L, Huang, Helen Q, Moore, Kathleen N, Tewari, Krishnansu S, Copeland, Larry J, Secord, Angeles A, Mutch, David G, Santin, Alessandro, Warshal, David P, Spirtos, Nick M, DiSilvestro, Paul A, Ioffe, Olga B, and Miller, David S

Subjects
Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinosarcoma, Disease-Free Survival, Female, Humans, Ifosfamide, Ovarian Neoplasms, Paclitaxel, Uterine Neoplasms, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThis phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS).Patients and methodsAdults with chemotherapy-naïve UCS or ovarian carcinosarcoma (OCS) were randomly assigned to PC or PI with 3-week cycles for 6-10 cycles. With 264 events in patients with UCS, the power for an overall survival (OS) hybrid noninferiority design was 80% for a null hazard ratio (HR) of 1.2 against a 13% greater death rate on PI with a type I error of 5% for a one-tailed test.ResultsThe study enrolled 536 patients with UCS and 101 patients with OCS, with 449 and 90 eligible, respectively. Primary analysis was on patients with UCS, distributed as follows: 40% stage I, 6% stage II, 31% stage III, 15% stage IV, and 8% recurrent. Among eligible patients with UCS, PC was assigned to 228 and PI to 221. PC was not inferior to PI. The median OS was 37 versus 29 months (HR = 0.87; 90% CI, 0.70 to 1.075; P < .01 for noninferiority, P > .1 for superiority). The median progression-free survival was 16 versus 12 months (HR = 0.73; P = < 0.01 for noninferiority, P < .01 for superiority). Toxicities were similar, except that more patients in the PC arm had hematologic toxicity and more patients in the PI arm had confusion and genitourinary hemorrhage. Among 90 eligible patients with OCS, those in the PC arm had longer OS (30 v 25 months) and progression-free survival (15 v 10 months) than those in the PI arm, but with limited precision, these differences were not statistically significant.ConclusionPC was not inferior to the active regimen PI and should be standard treatment for UCS.

Published
2022

2. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Author

Oonk, Maaike HM, Slomovitz, Brian, Baldwin, Peter JW, van Doorn, Helena C, van der Velden, Jacobus, de Hullu, Joanne A, Gaarenstroom, Katja N, Slangen, Brigitte FM, Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora BL, van Driel, Willemien J, Hermans, Ralph H, Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M, Sharma, Aarti, DiSilvestro, Paul A, Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B, Luesley, David, Ellis, Patricia, Duncan, Timothy J, Tjiong, Ming Y, Cruickshank, Derek J, Kjølhede, Preben, Levenback, Charles F, Bouda, Jiri, Kieser, Katharina E, Palle, Connie, Spirtos, Nicola M, O'Malley, David M, Leitao, Mario M, Geller, Melissa A, Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H, Borgfeldt, Christer, Lea, Jayanthi S, Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S, Manchanda, Ranjit, Jensen, Pernille T, Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H, Monk, Bradley J, Creutzberg, Carien L, and van der Zee, Ate GJ

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Middle Aged, Neoplasm Micrometastasis, Neoplasm Staging, Prospective Studies, Radiation Dosage, Sentinel Lymph Node, Time Factors, Treatment Outcome, Vulvar Neoplasms, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN).MethodsGROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences.ResultsFrom December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL.ConclusionInguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.

Published
2021

3. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Author

Miller, David S, Filiaci, Virginia L, Mannel, Robert S, Cohn, David E, Matsumoto, Takashi, Tewari, Krishnansu S, DiSilvestro, Paul, Pearl, Michael L, Argenta, Peter A, Powell, Matthew A, Zweizig, Susan L, Warshal, David P, Hanjani, Parviz, Carney, Michael E, Huang, Helen, Cella, David, Zaino, Richard, and Fleming, Gini F

Subjects
Clinical Research, Cancer, Clinical Trials and Supportive Activities, Mind and Body, 6.5 Radiotherapy and other non-invasive therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cisplatin, Endometrial Neoplasms, Female, Filgrastim, Humans, Middle Aged, Paclitaxel, Progression-Free Survival, Quality of Life, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeLimitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP.MethodsGOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints.ResultsFrom 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC (P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC.ConclusionWith demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.

Published
2020

4. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Author

Landen, Charles N., primary, Buckanovich, Ronald J., additional, Sill, Michael W., additional, Mannel, Robert S., additional, Walker, Joan L., additional, DiSilvestro, Paul A., additional, Mathews, Cara A., additional, Mutch, David G., additional, Hernandez, Marcia L., additional, Martin, Lainie P., additional, Bishop, Erin, additional, Gill, Sarah E., additional, Gordinier, Mary E., additional, Burger, Robert A., additional, Aghajanian, Carol, additional, Liu, Joyce F., additional, Moore, Kathleen N., additional, and Bookman, Michael A., additional

Published
2024
Full Text
View/download PDF

5. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Author

Walker, Joan, Brady, Mark, Fleming, Gini, Huang, Helen, DiSilvestro, Paul, Fujiwara, Keiichi, Alberts, David, Zheng, Wenxin, Cohn, David, Powell, Matthew, Van Le, Linda, Davidson, Susan, Gray, Heidi, Rose, Peter, Aghajanian, Carol, Myers, Tashanna, Alvarez Secord, Angeles, Rubin, Stephen, Mannel, Robert, Wenzel, Lari, and Tewari, Krishnansu

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, Disease Progression, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Infusions, Parenteral, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Progression-Free Survival, Time Factors, United States
Abstract

PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS: A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION: Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.

Published
2019

6. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Author

Sherman, Mark, Piedmonte, Marion, Mai, Phuong, Ioffe, Olga, Ronnett, Brigitte, Van Le, Linda, Ivanov, Iouri, Bell, Maria, Blank, Stephanie, DiSilvestro, Paul, Hamilton, Chad, Wakeley, Katie, Kauff, Noah, Yamada, S, Rodriguez, Gustavo, Skates, Steven, Alberts, David, Walker, Joan, Minasian, Lori, Lu, Karen, Greene, Mark, and Tewari, Krishnansu

Subjects
Adult, Biomarkers, Tumor, Breast Neoplasms, CA-125 Antigen, Fallopian Tube Neoplasms, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Humans, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasms, Unknown Primary, Ovarian Neoplasms, Ovariectomy, Risk Factors
Abstract

PURPOSE: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study. PARTICIPANTS AND METHODS: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participants mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression. RESULTS: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001). In multivariable models, positive BRCA1/2 mutation status (P = .0056), postmenopausal status (P = .0023), and abnormal CA-125 levels and/or TVU examinations (P < .001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign. CONCLUSION: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO. BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

Published
2014

7. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

Author

DiSilvestro, Paul, Ali, Shamshad, Craighead, Peter, Lucci, Joseph, Lee, Yi-Chun, Cohn, David, Spirtos, Nicola, Muller, Carolyn, Gajewski, Walter, Steinhoff, Margaret, Monk, Bradley, and Tewari, Krishnansu

Subjects
Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Canada, Carcinoma, Adenosquamous, Carcinoma, Squamous Cell, Chemoradiotherapy, Chi-Square Distribution, Cisplatin, Disease Progression, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Prospective Studies, Time Factors, Tirapazamine, Treatment Outcome, Triazines, United States, Uterine Cervical Neoplasms
Abstract

PURPOSE: This prospective, randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group was designed to test the effectiveness and safety of adding the hypoxic cell sensitizer tirapazamine (TPZ) to standard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer. PATIENTS AND METHODS: Patients with locally advanced cervix cancer were randomly assigned to CIS chemoradiotherapy versus CIS/TPZ chemoradiotherapy. Primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS) and tolerability. RESULTS: PFS was evaluable in 387 of 402 patients randomly assigned over 36 months, with enrollment ending in September 2009. Because of the lack of TPZ supply, the study did not reach its original target accrual goal. At median follow-up of 28.3 months, PFS and OS were similar in both arms. Three-year PFS for the TPZ/CIS/RT and CIS/RT arms were 63.0% and 64.4%, respectively (log-rank P = .7869). Three-year OS for the TPZ/CIS/RT and CIS/RT arms were 70.5% and 70.6%, respectively (log-rank P = .8333). A scheduled interim safety analysis led to a reduction in the starting dose for the TPZ/CIS arm, with resulting tolerance in both treatment arms. CONCLUSION: TPZ/CIS chemoradiotherapy was not superior to CIS chemoradiotherapy in either PFS or OS, although definitive commentary was limited by an inadequate number of events (progression or death). TPZ/CIS chemoradiotherapy was tolerable at a modified starting dose.

Published
2014

8. Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Author

Leath, Charles A., primary, Deng, Wei, additional, Mell, Loren K., additional, Richardson, Debra L., additional, Walker, Joan L., additional, Holman, Laura L., additional, Lea, Jayanthi Sivasothy, additional, Amarnath, Sudha R., additional, Santos-Reyes, Luis Javier, additional, Arend, Rebecca Christian, additional, Mayadev, Jyoti, additional, Jegadeesh, Naresh, additional, Disilvestro, Paul, additional, Chon, Hye Sook, additional, Ghamande, Sharad A., additional, Quick, Allison M, additional, Chino, Junzo P., additional, Mackay, Helen, additional, Aghajanian, Carol, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

9. A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Author

Landen, Charles N., primary, Buckanovich, Ronald J., additional, Sill, Michael, additional, Mannel, Robert S., additional, Walker, Joan L., additional, Disilvestro, Paul, additional, Mathews, Cara Amanda, additional, Mutch, David Gardner, additional, Hernandez, Marcia, additional, Martin, Lainie P., additional, Bishop, Erin, additional, Gill, Sarah, additional, Gordinier, Mary E, additional, Burger, Robert Allen, additional, Aghajanian, Carol, additional, Liu, Joyce F., additional, Moore, Kathleen N., additional, and Bookman, Michael A., additional

Published
2022
Full Text
View/download PDF

10. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

Author

DiSilvestro, Paul, Banerjee, Susana, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S., Gourley, Charlie, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William, Mathews, Cara, Liu, Joyce, McNamara, John, and Lowe, Elizabeth S.

Published
2023
Full Text
View/download PDF

12. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

Author

DiSilvestro, Paul, primary, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Kim, Byoung-Gie, additional, Oaknin, Ana, additional, Friedlander, Michael, additional, Lisyanskaya, Alla, additional, Floquet, Anne, additional, Leary, Alexandra, additional, Sonke, Gabe S., additional, Gourley, Charlie, additional, Banerjee, Susana, additional, Oza, Amit, additional, González-Martín, Antonio, additional, Aghajanian, Carol A., additional, Bradley, William H., additional, Mathews, Cara A., additional, Liu, Joyce, additional, Lowe, Elizabeth S., additional, Bloomfield, Ralph, additional, and Moore, Kathleen N., additional

Published
2020
Full Text
View/download PDF

13. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Author

Randall, Marcus E., primary, Filiaci, Virginia, additional, McMeekin, D. Scott, additional, von Gruenigen, Vivian, additional, Huang, Helen, additional, Yashar, Catheryn M., additional, Mannel, Robert S., additional, Kim, Jae-Weon, additional, Salani, Ritu, additional, DiSilvestro, Paul A., additional, Burke, James J., additional, Rutherford, Thomas, additional, Spirtos, Nick M., additional, Terada, Keith, additional, Anderson, Penny R., additional, Brewster, Wendy R., additional, Small, William, additional, Aghajanian, Carol A., additional, and Miller, David S., additional

Published
2019
Full Text
View/download PDF

14. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.

Author

Huang, Gloria S., primary, Merritt, Melissa A., additional, Hutson, Alan, additional, Strickler, Howard D., additional, Einstein, Mark, additional, Brouwer-Visser, Jurriaan, additional, Ramirez, Nilsa C., additional, Lankes, Heather A., additional, El-Bahrawy, Mona, additional, Xue, Xiaonan, additional, Yu, Herbert, additional, Mannel, Robert S., additional, O'Malley, David M., additional, Mutch, David Gardner, additional, Disilvestro, Paul, additional, Geller, Melissa Ann, additional, Guntupalli, Saketh R, additional, Birrer, Michael J., additional, Miller, David S., additional, and Gunter, Marc J., additional

Published
2019
Full Text
View/download PDF

15. Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.

Author

Friedlander, Michael, primary, Moore, Kathleen N., additional, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Kim, Byoung-Gie, additional, Oaknin, Ana, additional, Lisyanskaya, Alla Sergeevna, additional, Floquet, Anne, additional, Leary, Alexandra, additional, Sonke, Gabe S., additional, Gourley, Charlie, additional, Banerjee, Susana N., additional, Oza, Amit M., additional, González-Martín, Antonio, additional, Aghajanian, Carol, additional, Bradley, William Hampton, additional, Lowe, Elizabeth S., additional, Bloomfield, Ralph, additional, and Disilvestro, Paul, additional

Published
2019
Full Text
View/download PDF

16. Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

Author

Colombo, Nicoletta, primary, Moore, Kathleen N., additional, Scambia, Giovanni, additional, Oaknin, Ana, additional, Friedlander, Michael, additional, Lisyanskaya, Alla Sergeevna, additional, Floquet, Anne, additional, Leary, Alexandra, additional, Sonke, Gabe S., additional, Gourley, Charlie, additional, Banerjee, Susana N., additional, Oza, Amit M., additional, González-Martín, Antonio, additional, Aghajanian, Carol, additional, Bradley, William Hampton, additional, Kim, Jae-Weon, additional, Lowe, Elizabeth S., additional, Bloomfield, Ralph, additional, and Disilvestro, Paul, additional

Published
2019
Full Text
View/download PDF

17. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

Author

Mathews, Cara Amanda, primary, Moore, Kathleen N., additional, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Kim, Byoung-Gie, additional, Oaknin, Ana, additional, Friedlander, Michael, additional, Lisyanskaya, Alla Sergeevna, additional, Floquet, Anne, additional, Leary, Alexandra, additional, Sonke, Gabe S., additional, Gourley, Charlie, additional, Banerjee, Susana N., additional, Oza, Amit M., additional, González-Martín, Antonio, additional, Aghajanian, Carol, additional, Bradley, William Hampton, additional, Lowe, Elizabeth S., additional, Bloomfield, Ralph, additional, and Disilvestro, Paul, additional

Published
2019
Full Text
View/download PDF

18. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

Author

Moore, Kathleen N., primary, Secord, Angeles Alvarez, additional, Geller, Melissa Ann, additional, Miller, David S., additional, Cloven, Noelle Gillette, additional, Fleming, Gini F., additional, Wahner Hendrickson, Andrea Elisabeth, additional, Azodi, Masoud, additional, DiSilvestro, Paul, additional, Oza, Amit M., additional, Cristea, Mihaela C., additional, Berek, Jonathan S., additional, Chan, John K., additional, Li, Yong, additional, Clark, Romnee, additional, Matulonis, Ursula A., additional, and Monk, Bradley J., additional

Published
2018
Full Text
View/download PDF

19. Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.

Author

Matulonis, Ursula A., primary, Filiaci, Virginia L., additional, Huang, Helen Q, additional, Randall, Marcus, additional, Kim, Byoung, additional, DiSilvestro, Paul, additional, Moxley, Katherine M., additional, O'Malley, David M., additional, Powell, Matthew A., additional, Spirtos, Nicola M., additional, Tewari, Krishnansu Sujata, additional, Richards, William, additional, Nakayama, John, additional, Steinhoff, Margaret, additional, Mutch, David Gardner, additional, Miller, David S., additional, Wenzel, Lari B., additional, and Matei, Daniela, additional

Published
2018
Full Text
View/download PDF

20. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

Author

Matei, Daniela, primary, Filiaci, Virginia L., additional, Randall, Marcus, additional, Steinhoff, Margaret, additional, DiSilvestro, Paul, additional, Moxley, Katherine M., additional, Kim, Byoung, additional, Powell, Matthew A., additional, O'Malley, David M., additional, Spirtos, Nicola M., additional, Tewari, Krishnansu Sujata, additional, Richards, Wm Edward, additional, Nakayama, John, additional, Mutch, David Gardner, additional, and Miller, David S., additional

Published
2017
Full Text
View/download PDF

21. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Author

McMeekin, D. Scott, primary, Tritchler, David L., additional, Cohn, David E., additional, Mutch, David G., additional, Lankes, Heather A., additional, Geller, Melissa A., additional, Powell, Matthew A., additional, Backes, Floor J., additional, Landrum, Lisa M., additional, Zaino, Richard, additional, Broaddus, Russell D., additional, Ramirez, Nilsa, additional, Gao, Feng, additional, Ali, Shamshad, additional, Darcy, Kathleen M., additional, Pearl, Michael L., additional, DiSilvestro, Paul A., additional, Lele, Shashikant B., additional, and Goodfellow, Paul J., additional

Published
2016
Full Text
View/download PDF

22. A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

Author

Gonzalez-Martin, Antonio, primary, Backes, Floor Jennishens, additional, Baumann, Klaus H., additional, Chase, Dana Meredith, additional, Fehr, Mathias Konrad, additional, Coleman, Robert L., additional, Freyer, Gilles, additional, DiSilvestro, Paul, additional, Lavie, Ofer, additional, Herzog, Thomas J., additional, Lorusso, Domenica, additional, Moore, Kathleen N., additional, Mirza, Mansoor Raza, additional, O'Cearbhaill, Roisin Eilish, additional, Vergote, Ignace, additional, Pothuri, Bhavana, additional, Balser, John, additional, Agarwal, Shefali, additional, and Monk, Bradley J., additional

Published
2016
Full Text
View/download PDF

25. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

Author

Goodfellow, Paul J., primary, Billingsley, Caroline C., additional, Lankes, Heather A., additional, Ali, Shamshad, additional, Cohn, David E., additional, Broaddus, Russell J., additional, Ramirez, Nilsa, additional, Pritchard, Colin C., additional, Hampel, Heather, additional, Chassen, Alexis S., additional, Simmons, Luke V., additional, Schmidt, Amy P., additional, Gao, Feng, additional, Brinton, Louise A., additional, Backes, Floor, additional, Landrum, Lisa M., additional, Geller, Melissa A., additional, DiSilvestro, Paul A., additional, Pearl, Michael L., additional, Lele, Shashikant B., additional, Powell, Matthew A., additional, Zaino, Richard J., additional, and Mutch, David, additional

Published
2015
Full Text
View/download PDF

26. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Author

Rose, Peter G., primary, Java, James, additional, Whitney, Charles W., additional, Stehman, Frederick B., additional, Lanciano, Rachelle, additional, Thomas, Gillian M., additional, and DiSilvestro, Paul A., additional

Published
2015
Full Text
View/download PDF

27. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high risk endometrial cancer.

Author

Atri, Mostafa, primary, Zhang, Zheng, additional, Dehdashti, Farrokh, additional, Koh, Wui-Jin, additional, Ali, Shamshad, additional, Mannel, Robert S., additional, Moxley, Katherine, additional, DiSilvestro, Paul, additional, Pearl, Michael, additional, King, Stephen Duane Watkins, additional, Plante, Marie, additional, Zhou, xunClare, additional, and Gold, Michael, additional

Published
2015
Full Text
View/download PDF

28. CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.

Author

Lee, Ting-Yim, primary, Ng, Chaan S., additional, Zhang, Zheng, additional, Lee, Susanna, additional, Marques, Helga, additional, Burgers, Kyle, additional, Su, Feng, additional, Bauza, Joseph, additional, Mannel, Robert S., additional, Walker, Joan L., additional, Huh, Warner King, additional, Rubin, Stephen C., additional, DiSilvestro, Paul, additional, Martin, Lainie P., additional, Chan, John K., additional, Bookman, Michael A., additional, and Coleman, Robert L., additional

Published
2015
Full Text
View/download PDF

29. A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study.

Author

Thaker, Premal H., primary, Brady, William E, additional, Lankes, Heather A., additional, Cohn, David E., additional, Aghajanian, Carol, additional, Mutch, David Gardner, additional, Mannel, Robert S., additional, Bell-McGuinn, Katherine M., additional, DiSilvestro, Paul, additional, Jelovac, Danijela, additional, Carter, Jori S., additional, and Salani, Ritu, additional

Published
2015
Full Text
View/download PDF

30. Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer.

Author

Atri, Mostafa, primary, Zhang, Zheng, additional, Dehdashti, Farrokh, additional, Lee, Susanna, additional, Ali, Shamshad, additional, Koh, Wui-Jin, additional, Moore, Kathleen N., additional, Landrum, Lisa Michelle, additional, Kim, Jae-Weon, additional, DiSilvestro, Paul, additional, Eisenhauer, Eric Lawernce, additional, Schnell, Frederick M., additional, and Gold, Michael, additional

Published
2015
Full Text
View/download PDF

32. Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199.

Author

Mai, Phuong L., primary, Sherman, Mark E, additional, Piedmonte, Marion, additional, Ioffe, Olga B., additional, Ronnett, Brigitte M., additional, Van Le, Linda, additional, Mutch, David Gardner, additional, Cohn, David E., additional, Thigpen, J. Tate, additional, Tewari, Krishnansu Sujata, additional, Disilvestro, Paul, additional, Kauff, Noah D., additional, Lu, Karen H., additional, and Greene, Mark H., additional

Published
2012
Full Text
View/download PDF

33. Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

Author

Penson, Richard T., primary, Dizon, Don S., additional, Cannistra, Stephen A., additional, Roche, Maria R., additional, Krasner, Carolyn N., additional, Berlin, Suzanne T., additional, Horowitz, Neil S., additional, DiSilvestro, Paul A., additional, Matulonis, Ursula A., additional, Lee, Hang, additional, King, Modjulie A., additional, and Campos, Susana M., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results